Lupin launches Mycophenolate Mofetil Capsules

Lupin has launched Mycophenolate Mofetil Capsules USP, 250 mg. The shares could be in focus on the following trading day as a reaction to the launch.

The company’s alliance partner Concord Biotech (Concord) had received an approval from the United States Food and Drug Administration (USFDA) earlier for the said capsule.

Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche’s CellCept. Mycophenolate Mofetil Capsules are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immune suppressants.

According to IQVIA MAT August 2019 stats, Mycophenolate Mofetil Capsules USP, 250 mg, had annual sales of approximately $53 million in the United States.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. 

The shares of Lupin on Friday opened at Rs. 701.05 as against Thursday’s close of Rs. 701.05. At closing hours it was trading at Rs. 686.60, losing 2.06 per cent compared to its previous close.